Alabama Cannabis
Market Intelligence Report

Alabama's medical cannabis program reached a genuine milestone on June 4, 2026, when Callie's Apothecary became the state's first operating dispensary — serving 102 patients and generating nearly $15,000 in sales in its opening week. The moment caps years of delay: the Alabama Medical Cannabis Commission (AMCC) voided an initial round of dispensary license awards over scoring inconsistencies, faced lawsuits from passed-over applicants alleging a discriminatory process, and was separately sued by parents over delayed patient access to medicine.

The patient registry only opened in late April 2026, certifying roughly 200 patients by mid-May before climbing to 446 approved Medical Cannabis Cards by early June, supported by 21 licensed physicians. The AMCC has issued 9 cultivation licenses and 4 processor licenses, plus licenses to 3-4 dispensary companies (each permitted up to 3 storefronts), with additional store openings expected through the summer of 2026.

Alabama's population of just over 5 million, with household income below the national median, forms the long-run addressable base for a medical program that has only just begun serving patients. (Official, Census ACS 2024)

Alabama's medical cannabis program is regulated by the Alabama Medical Cannabis Commission (AMCC) under the Darren Wesley "Ato" Hall Compassion Act (2021). The rollout has been unusually litigious: the AMCC voided its initial dispensary license awards after identifying "potential inconsistencies" in how applications were scored, drawing lawsuits from companies that argued the revised process was discriminatory, while a separate suit from five parents challenged the pace of patient access. The commission distributed licenses to three dispensary companies, with a fourth approved in late January 2026 following an administrative law judge's recommendation.

Alabama's primary cost-relief mechanism so far has been a temporary fee reduction tied to the program's litigation-driven delays, rather than a social equity program.

Alabama's cannabis supply chain is only beginning to take shape: 9 cultivators and 4 processors hold licenses, feeding a product menu restricted to capsules, tinctures, metered inhalers, and transdermal patches. Smokable flower, vaping products, and edibles remain prohibited under the program, a significant structural difference from most other medical-only states in this report set and one that shapes cultivation and processing economics from the outset.

Alabama's registered patient base remains extremely small at this stage — 446 approved cards as of early June 2026 — reflecting a registry that only opened in late April 2026, weeks before the first dispensary began serving patients. (Official)

Alabama's licensed dispensary companies are permitted up to 3 storefronts each statewide, but with only one dispensary (Callie's Apothecary) actually open as of this report, no meaningful county-level distribution pattern yet exists. The AMCC has not published a county-by-county sales breakdown. (Not Available for county-level detail; program too early-stage to assess geographic distribution.)

Alabama's published licensing fees are among the data points available this early in the program; full buildout cost benchmarks are still emerging.

Vendor demand signal tracks which product and service categories Alabama's newly licensed cultivators, processors, and dispensary operators are sourcing as the program ramps up.

Alabama funds the AMCC through a combination of business license fees and a 9% privilege tax on gross medical cannabis sales. With only one dispensary open for roughly one week as of this report (generating about $15,000 in sales), no meaningful statewide tax revenue figure yet exists — this is a data point to revisit as additional dispensaries open through the summer of 2026.

Alabama borders four states spanning medical-only programs of varying maturity alongside full prohibition.

Alabama does not yet publish a consolidated cannabis employment figure, given that the program's first dispensary opened only on June 4, 2026; meaningful workforce data will emerge as more of the 9 cultivation, 4 processor, and 3-4 dispensary licensees begin operations. (Not Available.)

Alabama's program does not include a dedicated social equity licensing track; the temporary 25% license fee reduction was framed as relief from litigation-driven delay costs rather than an equity measure. Litigation over the fairness of the original license-scoring process remains a live issue for the program. (Official.)

Alabama does not publish an illicit cannabis market size estimate. With legal access limited to 446 registered patients and a single operating dispensary as of this report, unregulated demand almost certainly exceeds the legal market by a wide margin, though no official figure quantifies this. (Not Available.)

This report blends official AMCC licensing, patient registry, and fee data, Alabama Department of Revenue tax information, reputable trade press coverage of the program's litigation history and launch week, and federal demographic sources.

This report compiles data from the Alabama Medical Cannabis Commission, the Alabama Department of Revenue, reputable cannabis trade press, and federal demographic sources.